Satio
Satio is dedicated to providing technology solutions for diagnostics and therapeutics to the consumer worldwide. The company focuses on transforming traditional blood collection, diagnostics, and drug delivery through innovative, low-cost, and painless solutions. Satio develops platforms including reusable drug delivery patches, blood sampling patches for lab testing, and consumer-based diagnostic patches, aiming to make healthcare more accessible, efficient, and patient-friendly. The company collaborates with pharmaceutical companies, laboratories, and research institutions to advance healthcare technology and global health outcomes.
Industries
Nr. of Employees
small (1-50)
Satio
27 Drydock Avenue, 3rd Floor, Boston, MA 02210, USA
Patents
Products
Dried blood spot collection patch (consumer DBS)
A lancet-activated adhesive patch for painless upper-arm dried blood spot collection designed for home self-collection and shipment to clinical laboratories for diagnostic and genomic testing.
Whole blood collection patch (consumer whole blood)
An adhesive patch system that collects 50–150 µL of whole blood from the upper arm into an integrated tube for laboratory-developed tests and whole-genome sequencing workflows.
Point-of-care diagnostic patch with LFA/biosensor integration
A compact patch that combines blood draw and on‑device diagnostic readout using lateral flow assays and biosensor modules to deliver rapid results at the point of need.
Reusable applicator with disposable hollow microneedle delivery patch
A reusable motor-driven applicator paired with a disposable patch housing a standard drug cartridge, hollow microneedle array, adhesive, pressure/go-no-go sensors and NFC for remotely controlled intradermal or subcutaneous drug and vaccine delivery.
Dried blood spot collection patch (consumer DBS)
A lancet-activated adhesive patch for painless upper-arm dried blood spot collection designed for home self-collection and shipment to clinical laboratories for diagnostic and genomic testing.
Whole blood collection patch (consumer whole blood)
An adhesive patch system that collects 50–150 µL of whole blood from the upper arm into an integrated tube for laboratory-developed tests and whole-genome sequencing workflows.
Point-of-care diagnostic patch with LFA/biosensor integration
A compact patch that combines blood draw and on‑device diagnostic readout using lateral flow assays and biosensor modules to deliver rapid results at the point of need.
Reusable applicator with disposable hollow microneedle delivery patch
A reusable motor-driven applicator paired with a disposable patch housing a standard drug cartridge, hollow microneedle array, adhesive, pressure/go-no-go sensors and NFC for remotely controlled intradermal or subcutaneous drug and vaccine delivery.
Services
Collaborative integration of lateral flow and biosensor assays into adhesive patch collection and point-of-care form factors for consumer market expansion.
Collaboration with CLIA labs to accept dried blood spot and whole blood samples collected via adhesive patches for laboratory-developed tests and genomic analysis.
Co-development and integration services to adapt patch-based microneedle delivery and reusable applicators for pharmaceutical and vaccine candidates, including telehealth-enabled remote administration models.
Collaboration with contract manufacturers and packaging/filling technology providers to enable high-volume, low-cost manufacturing and distribution strategies for diagnostics and delivery disposables.
Collaborative integration of lateral flow and biosensor assays into adhesive patch collection and point-of-care form factors for consumer market expansion.
Collaboration with CLIA labs to accept dried blood spot and whole blood samples collected via adhesive patches for laboratory-developed tests and genomic analysis.
Co-development and integration services to adapt patch-based microneedle delivery and reusable applicators for pharmaceutical and vaccine candidates, including telehealth-enabled remote administration models.
Collaboration with contract manufacturers and packaging/filling technology providers to enable high-volume, low-cost manufacturing and distribution strategies for diagnostics and delivery disposables.
Expertise Areas
- At‑home blood collection and sample containment
- Intradermal and subcutaneous microneedle drug delivery
- Point‑of‑care and on‑device diagnostics
- Clinical development and late‑stage device testing
Key Technologies
- Hollow microneedle arrays
- Adhesive patch sampling platforms
- Dried blood spot (DBS) collection
- Upper-arm whole blood collection (50–150 µL)
News & Updates
Satio announced a $3.5 million SBIR contract from ARPA-H to develop a compact, inexpensive, remotely controllable transdermal drug delivery device with disposable microneedle components, designed for home use to improve treatment adherence and expand access.
Satio and Nanowear partner to advance home-based diagnostic and therapeutic care, integrating nanotechnology biomarker diagnostics with blood draw systems for precision therapeutics and AI-based risk assessment.
Satio completes a groundbreaking ARPA-H funded project developing a remotely controllable microneedle drug delivery device designed for home use, enabling precise, controlled, and potentially pain-free drug administration.
Satio announced a $3.5 million SBIR contract from ARPA-H to develop a compact, inexpensive, remotely controllable transdermal drug delivery device with disposable microneedle components, designed for home use to improve treatment adherence and expand access.
Satio and Nanowear partner to advance home-based diagnostic and therapeutic care, integrating nanotechnology biomarker diagnostics with blood draw systems for precision therapeutics and AI-based risk assessment.
Satio completes a groundbreaking ARPA-H funded project developing a remotely controllable microneedle drug delivery device designed for home use, enabling precise, controlled, and potentially pain-free drug administration.